VKTX vs. LLY
Compare and contrast key facts about Viking Therapeutics, Inc. (VKTX) and Eli Lilly and Company (LLY).
Performance
VKTX vs. LLY - Performance Comparison
Loading graphics...
VKTX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VKTX Viking Therapeutics, Inc. | -7.50% | -12.57% | 116.23% | 97.98% | 104.35% | -18.29% | -29.80% | 4.84% | 88.42% | 241.18% |
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Fundamentals
VKTX:
$3.71B
LLY:
$825.96B
VKTX:
-$3.19
LLY:
$22.96
VKTX:
5.80
LLY:
31.13
VKTX:
$0.00
LLY:
$65.18B
VKTX:
-$208.00K
LLY:
$54.62B
VKTX:
-$393.01M
LLY:
$27.94B
Returns By Period
In the year-to-date period, VKTX achieves a -7.50% return, which is significantly higher than LLY's -14.27% return. Over the past 10 years, VKTX has outperformed LLY with an annualized return of 36.40%, while LLY has yielded a comparatively lower 30.92% annualized return.
VKTX
- 1D
- 8.76%
- 1M
- -3.84%
- YTD
- -7.50%
- 6M
- 23.82%
- 1Y
- 34.74%
- 3Y*
- 25.03%
- 5Y*
- 38.96%
- 10Y*
- 36.40%
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VKTX vs. LLY — Risk / Return Rank
VKTX
LLY
VKTX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| VKTX | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.44 | 0.29 | +0.16 |
Sortino ratioReturn per unit of downside risk | 1.10 | 0.69 | +0.41 |
Omega ratioGain probability vs. loss probability | 1.17 | 1.10 | +0.07 |
Calmar ratioReturn relative to maximum drawdown | 0.60 | 0.42 | +0.18 |
Martin ratioReturn relative to average drawdown | 1.32 | 1.02 | +0.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| VKTX | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.44 | 0.29 | +0.16 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.39 | 1.23 | -0.84 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.37 | 1.04 | -0.67 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.12 | 0.56 | -0.44 |
Correlation
The correlation between VKTX and LLY is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
VKTX vs. LLY - Dividend Comparison
VKTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
VKTX Viking Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
VKTX vs. LLY - Drawdown Comparison
The maximum VKTX drawdown since its inception was -90.41%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for VKTX and LLY.
Loading graphics...
Drawdown Indicators
| VKTX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.41% | -68.24% | -22.17% |
Max Drawdown (1Y)Largest decline over 1 year | -45.14% | -30.26% | -14.88% |
Max Drawdown (5Y)Largest decline over 5 years | -78.86% | -34.48% | -44.38% |
Max Drawdown (10Y)Largest decline over 10 years | -89.26% | -34.48% | -54.78% |
Current DrawdownCurrent decline from peak | -65.57% | -17.00% | -48.57% |
Average DrawdownAverage peak-to-trough decline | -59.92% | -19.25% | -40.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.31% | 12.39% | +7.92% |
Volatility
VKTX vs. LLY - Volatility Comparison
Viking Therapeutics, Inc. (VKTX) has a higher volatility of 18.20% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| VKTX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.20% | 9.04% | +9.16% |
Volatility (6M)Calculated over the trailing 6-month period | 45.65% | 26.21% | +19.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 78.68% | 42.44% | +36.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 101.68% | 32.14% | +69.54% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 99.00% | 29.80% | +69.20% |
Financials
VKTX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities